Immunotherapy after Chemo-Radiation shows promise for nasopharyngeal cancer
NCT ID NCT04227509
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tested whether adding the immunotherapy drug pembrolizumab after standard chemoradiation helps control advanced nasopharyngeal cancer. Fifty-three patients received up to 17 cycles (about 1 year) of pembrolizumab. The main goal was to see how many patients remained cancer-free or alive at 3 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Internal Medicine, Seoul National University Hospital
Seoul, 110-744, South Korea
Conditions
Explore the condition pages connected to this study.